Development and preclinical evaluation of KDTV001, an adenovirus 5-vectored trivalent HPV therapeutic vaccine targeting HPV16/18/52
{{output}}
Background: Persistent high-risk HPV infections (e.g., HPV16/18/52) are directly linked to cervical cancer development, thus necessitating the development of effective multi-target therapeutic vaccines. ... ...
